FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation By Ogkologos - November 20, 2025 298 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KO-MEN-001 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel August 26, 2025 New Vaccine Stimulates Survivors’ Immune Systems to Keep Triple-Negative Cancer from... February 14, 2020 Proof of Concept for the Safety and Immunogenicity of Lymph Node... January 18, 2024 K9 Police Officer In Berlin Beats Breast Cancer For Second Time March 7, 2019 Load more HOT NEWS Is Proton Therapy Safer than Traditional Radiation? How I Took Charge of My Cancer Care and Found a... Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... EMA Recommends Extension of Indications for Osimertinib
